Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Kobayashi Declares Bid for LDP Race, Urges More Investment in Pharma
August 20, 2024
- MHLW to Present Detailed Criteria for Exclusion from “Specified Clinical Trials”
August 20, 2024
- Certain Jabs to Be Exempted from Regenerative Medicine Safety Act to Facilitate Travel Vaccination
August 20, 2024
- Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
- Eisai’s ALS Therapy, Amgen’s TED Drug Up for Review on Aug. 26
August 19, 2024
- August Generic Approval List Includes AGs for at Least 3 APIs, Acofide and More
August 19, 2024
- Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
- MHLW Announces Simplified New Process for Drug Delisting
August 19, 2024
- JGA Shares Scheme of Supply Managers Council, MHLW Conferring with FTC on Feasibility
August 9, 2024
- Chuikyo Urges Rethink of Health Coverage for Conditionally Approved Regenerative Medicines
August 9, 2024
- Pharma Opposes Off-Year Revision, but Payer Pushes Implementation as Premise
August 8, 2024
- Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
- Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
- Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
August 8, 2024
- AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
August 8, 2024
- MHLW to Issue Guidance for Setting Acceptable Limit for Nitrosamines This Fall
August 6, 2024
- MHLW to Streamline Deliberations on JP Revisions to Facilitate Use of Overseas APIs
August 6, 2024
- Humira Gets Health Coverage for nr-axSpA
August 6, 2024
- Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
August 5, 2024
- Off-Year Debate Would Explore Ways to Address Drug Loss, Supply Issues with Drug Prices: Vice Minister
August 2, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…